SaaS sales still going ahead

Kneat (TSX-V: KSI) is pleased to announce it has signed a three-year Software as a Service (SaaS) Master Agreement with another top ten pharmaceutical company.

This global pharmaceutical company with more than 25,000 employees across multiple global facilities, joins the fast-growing group of tier one pharmaceutical companies who have selected Kneat’s SaaS Platform. The customer’s goal is end-to-end digitalization of many of its regulated GMP testing processes, with an initial focus on Commissioning, Qualification and Verification (CQV).…


Kneat (TSX-V: KSI) is a penny stock company with 60 employees…

Denny Schlesinger